Puritan Bennett(TM) 980 Ventilator (Photo: Business Wire)

Covidien plc (NYSE: COV), a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced its Puritan Bennett™ 980 ventilator has received European Economic Area (EEA) CE Mark approval.
Puritan Bennett(TM) 980 ventilator (Photo: Business Wire)

Puritan Bennett(TM) 980 ventilator (Photo: Business Wire)

The new acute care ventilator from Covidien—designed to be simple, safe and smart—helps enable patients, from neonatal to adult, to breathe more naturally through some of the most innovative breath technology available.

“We are excited to introduce our next-generation acute ventilation platform, the Puritan Bennett 980 ventilator,” said Cristiano Franzi, president, Europe, Covidien. “Building on Covidien’s strong legacy of innovation, the Puritan Bennett 980 ventilator will provide clinicians with a simple, safe and smart way to care for patients.”

The Puritan Bennett 980 ventilator system is for patients ranging from neonatal to adult. The ventilator system was also approved for commercial distribution in the U.S., Japan and Canada and will be available for sale in those countries as well as the EEA in the coming months. For more information about the Puritan Bennett 980 ventilator, please visit www.covidien.com/PB980.

Compared to conventional mechanical ventilation

ABOUT COVIDIENCovidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien develops, manufactures and sells a diverse range of industry-leading medical device and supply products. With 2013 revenue of $10.2 billion, Covidien has more than 38,000 employees worldwide in more than 70 countries, and its products are sold in over 150 countries. Please visit www.covidien.com to learn more about our business.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140303005184/en/

Copyright Business Wire 2010

If you liked this article you might like

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Mallinckrodt Buys Ikaria in $2.3 Billion Hospital Treatment Deal

Stryker and Smith & Nephew Are the Stars to Watch in Medtech's 2015 Merger Dance

Medtronic Avoids U.S. Taxes While Saddling Shareholders With a Hefty Tax Bill

Trim Positions in Stryker Ahead of Fourth-Quarter Earnings; Buy on Pullback